



Food and Drug Administration
Rockville MD 20857

JAN 20 1999

Robert C. Seidman, PharmD, MPH
Vice President
Blue Cross of California Pharmacy
21555 Oxnard Street
Woodland Hills, CA 91367

Re: Docket No. 98P-0610/CP1

Dear Dr. Seidman:

I am writing to inform you that the Food and Drug Administration has not yet resolved the issues raised in your citizen petition submitted on July 24, 1998. Your petition requests that the Agency convert Allegra, Allegra-D, Claritin, Claritin-D, Claritin-D 24 Hour, Claritin-DS, Claritin Syrup, Zyrtec, and Zyrtec Syrup to over-the-counter status.

FDA has been unable to reach a decision on your petition because it raises complex issues requiring extensive review and analysis by Agency officials. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as we have reached a decision on your request.

Sincerely yours,

Janet Woodcock, M.D.
Director
Center for Drug Evaluation and Research

2154
JAN 25 1999

98P-0610

LET2